FDA Approves Avlayah In Hunter Syndrome Neurologic Manifestations
FDA approved Avlayah for pediatric Hunter syndrome, delivering enzyme therapy across the blood-brain barrier to address neurologic symptoms and improve developmental outcomes in affected children.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.